

| <i>Short Name</i>                   | <i>Comments</i>  | <i>Type</i> | <i>Investigator</i>                                   | <i>Contact</i>  |
|-------------------------------------|--|-------------|---|---|
| <b><i>Disease site specific</i></b> |  |             |   |   |
| <b><i>Treatment</i></b>             |  |             |   |   |
| CP-MGA271-03                        | Macrogenics Protocol CP-MGA271-03: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers                                      | Treatment   | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| SWOG S1320                          | Stage IV/Unresectable Stage III, No Prior MEKinhib. BRAFV600E or BRAFV600K Mutant Melanoma; Intermittent vs Continuous Dosing of <b><i>Dabrafenib &amp; Trametinib</i></b><br><a href="#">For More Information</a>   | Treatment   | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EA6134                              | Stage III/IV, Unresectable, BRAFV600 Mutant Melanoma, 1 <sup>st</sup> Line Mets/ <b><i>Dabrafenib + Trametinib</i></b> followed by <b><i>Ipilimumab + Nivolumab</i></b> at Progression vs. <b><i>Ipilimumab + Nivolumab</i></b> followed by <b><i>Dabrafenib + Trametinib</i></b> at Progression<br><a href="#">For More Information</a> | Treatment   | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EA6141                              | STAGE III/IV/Unresectable Melanoma; <b><i>Nivolumab plus Ipilimumab plus Sargramostim</i></b> versus <b><i>Nivolumab plus Ipilimumab</i></b> ; Phase II/III Trial<br><a href="#">For More Information</a>  | Treatment   | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| CTSU E3612                          | UNRESECTABLE/STAGE III or IV; 1 <sup>st</sup> or 2 <sup>nd</sup> Line. Phase II Trial of <b><i>Ipilimumab</i></b> with or without Bevacizumab<br><a href="#">For More Information</a>  | Treatment   | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

|   |   |           |   |  |
|---|---|-----------|---|--|
| <b>S1616</b>  | <b>A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-Pd-L1 Agent</b>                     | Treatment | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
|   | <a href="#">For More Information</a>  |           |   |  |
| <b>SWOG S1404</b>                                   | <b>RESECTED: A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma</b>                | Treatment | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
|   | <a href="#">For More Information</a>  |           |   |  |
| <b>Protocols that are NOT disease site specific</b> |   |           |   |  |
| <b>Treatment</b>                                    |   |           |   |  |
| <b>Alexion ALXN6000-ONC-102</b>                     | <b>Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer</b> | Treatment | <a href="#">START Midwest Investigators</a>   | START Midwest<br>(616) 954-5554                          |
|   | <b>A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</b> | Treatment | <a href="#">START Midwest Investigators</a>   | START Midwest<br>(616) 954-5554                          |
| <b>BGB-290</b>                                      | <b>A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</b>              | Treatment | <a href="#">START Midwest Investigators</a>   | START Midwest<br>(616) 954-5554                          |
|   | <b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas</b>                                       | Treatment | <a href="#">START Midwest Investigators</a>   | START Midwest<br>(616) 954-5554                          |

|                           |   |           |   |                                 |
|---------------------------|---|-----------|---|---------------------------------|
|                           | <b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors</b>   | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
|                           | <b>A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</b> | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>ALEXO<br/>AT148001</b> | <b>Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
|                           | <b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>SCI-CD47-001</b>       | <b>First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>MK-4280-001</b>        | <b>A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>LZM009-001</b>         | <b>A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |

|                             |   |           |   |                                 |
|-----------------------------|---|-----------|---|---------------------------------|
| <b>ASN002</b>               | <b>A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>20150195<br/>AMG 820</b> | <b>A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>R3767-ONC-<br/>1613</b>  | <b>A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies</b> | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>CP-MGA012-01</b>         | <b>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>APX_CLN_0011</b>         | <b>A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>CPI-1205-202</b>         | <b>A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors</b>                       | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>MK-4820</b>              | <b>A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |

|                     |   |           |   |   |
|---------------------|---|-----------|---|---|
| <b>ASN003-101</b>   | <b>A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>MK-8353-013</b>  | <b>A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>5F9004</b>       | <b>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>CP-MGA012-01</b> | <b>A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>CVM-001</b>      | <b>A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>NRG CC003</b>    | <b>Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</b><br><br><a href="#">For More Information</a>             | Treatment | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| <b>NRG CC001</b>    | <b>A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases</b><br><br><a href="#">For More Information</a> | Treatment | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

|                                   |   |                        |   |   |
|-----------------------------------|---|------------------------|---|---|
| A071401                           | Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations<br><br><a href="#">For More Information</a>  | Treatment              | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| ACCRU 2018-03                     | Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Melanoma<br><br><a href="#">For More Information</a>  | Other                  | <a href="#">CRCWM Physician</a>               | CRCWM<br>(616) 391-1230   |
| <b><i>Molecular Profiling</i></b> |   |                        |   |   |
| QOL Multisite<br>EAQ-152          | EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Adevanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling<br><br><a href="#">For More Information</a> | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - MATCH                    | MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131                            | <i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - A                        | Solid Tumors (Other than SC & NSCLC) or Lymphomas; <i>Afatinib</i> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

|             |   |                        |   |   |
|-------------|---|------------------------|---|---|
| EAY131 - B  | Tumors with HER2 Activating Mutations; Treatment: <u><i>Afatinib</i></u>  | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - C1 | <u><i>Crizotinib</i></u> in Patients with Tumors with MET Amplification   | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - C2 | <u><i>Crizotinib</i></u> in Patients with Tumors with MET Exon 14 Deletion  | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - E  | Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u><i>AZD9291</i></u>                            | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - F  | Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u><i>Crizotinib</i></u>                                     | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - G  | ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u><i>Crizotinib</i></u>   | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |
| EAY131 - H  | Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u><i>Dabrafenib</i></u> and <u><i>Trametinib</i></u> | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>  |                        |   |   |

|             |  |                     |   |   |
|-------------|--|---------------------|---|---|
| EAY131 - J  | <b><u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification</b>               | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - L  | <b>Phase II Study of MLN0128 (<u>TAK-228</u>) in Patients with Tumors with mTOR Mutations</b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - M  | <b>Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations</b>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - R  | <b>BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u></b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - S1 | <b><u>Trametinib</u> in Patients with Tumors with NF1 Mutations</b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - S2 | <b><u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations</b>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - T  | <b>Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449 (vismodegib)</u></b> | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                     |   |   |



|              |  |                     |   |   |
|--------------|--|---------------------|---|---|
| EAY131 - V   | <b>Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <i>Sunitinib</i></b><br><br><a href="#">For More Information</a>                                    | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - W   | <b>Phase II Study of <i>AZD4547</i> in Patients with Tumors with Aberrations in the FGFR Pathway</b><br><br><a href="#">For More Information</a>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - X   | <b><i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations</b><br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - Y   | <b><i>AZD5363</i> in Patients with Tumors with AKT Mutations</b><br><br><a href="#">For More Information</a>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - Z1A | <b><i>Binimetinib</i> in Patients with Tumors (Other than Melanoma) with NRAS Mutations</b><br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - Z1B | <b>MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC</b><br><br><a href="#">For More Information</a> | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| EAY131 - Z1D | <b><i>Nivolumab</i> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)</b><br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |

|                      |  |                     |   |   |
|----------------------|--|---------------------|---|---|
| EAY131 - Z1E         | Testing <b><u>LOXO-101</u></b> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes  |                     | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                      | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Z1I         | Testing <b><u>AZD1775</u></b> as a Possible Treatment in People who have Cancer with BRCA Mutations  |                     | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                      | <a href="#">For More Information</a>   |                     |   |   |
| ASCO TAPUR           | Targeted Agent and Profiling Utilization Registry Study. <b><u>All Drugs Provided</u></b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                      | <a href="#">For More Information</a>   |                     |   |   |
| <b>Biorepository</b> |  |                     |   |   |
| NCI PDM 9846         | Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)   | Biobanking          | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                      | <a href="#">For More Information</a>   |                     |   |   |
| SHARE                | <b>The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators</b>  | Biobanking          | Cottingham, Sandra                            | Spectrum Health Biorepository<br><a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a><br>(616) 267-2629 |
|                      | <i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i> |                     |   |   |

**Assessment/ Education**

|                              |   |       |   |   |
|------------------------------|---|-------|---|---|
| <b>URCC 13059<br/>GAP-70</b> | <b>Geriatric Assessment Intervention for Patients Aged 70 and Over<br/>Receiving Chemotherapy for Advanced Cancer: Reducing<br/>Chemotherapy Toxicity in Older Adults</b> | Other | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                              | <a href="#">For More Information</a>  |       |   |   |

**Symptom Management**

|                             |  |                       |   |   |
|-----------------------------|--|-----------------------|---|---|
| <b>S1415CD</b>              | <b>A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating<br/>Factor Standing Order Intervention and to Determine the<br/>Effectiveness of Colony Stimulating Factor Use as Prophylaxis for<br/>Patients Receiving Chemotherapy with Intermediate Risk for Febrile<br/>Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk<br/>(TrACER)</b> | Symptom<br>Management | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                             | <a href="#">For More Information</a>   |                       |   |   |
| <b>URCC 04040<br/>YOCAS</b> | <b>A Randomized Clinical Trial Comparing the Effectiveness of Yoga,<br/>Survivorship Health Education, and Cognitive Behavioral Therapy for<br/>Treating Insomnia in Cancer Survivors</b>  | Symptom<br>Management | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                             | <a href="#">For More Information</a>   |                       |   |   |
| <b>URCC 16070</b>           | <b>Treatment of Refractory Nausea</b>  | Symptom<br>Management | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                             | <a href="#">For More Information</a>   |                       |   |   |